The estimated Net Worth of Alane P Barnes is at least $4.73 Milion dollars as of 13 May 2024. Ms. Barnes owns over 5,000 units of Biocryst Pharmaceuticals stock worth over $2,324,890 and over the last 11 years she sold BCRX stock worth over $1,077,974. In addition, she makes $1,331,090 as Senior Vice President i Chief Legal Officer and Corporate Secretary at Biocryst Pharmaceuticals.
Sign up
Ms. Barnes BCRX stock SEC Form 4 insiders trading
Alane has made over 15 trades of the Biocryst Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of BCRX stock worth $27,650 on 13 May 2024.
The largest trade she's ever made was exercising 138,632 units of Biocryst Pharmaceuticals stock on 11 May 2021 worth over $594,731. On average, Alane trades about 7,186 units every 77 days since 2014. As of 13 May 2024 she still owns at least 300,762 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Ms. Barnes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alane Barnes biography
Alane P. Barnes serves as Senior Vice President, Chief Legal Officer and Corporate Secretary of the Company. She joined BioCryst in July 2006 as its General Counsel. She was named Corporate Secretary in 2007, was named Vice President, General Counsel & Corporate Secretary in 2011, and was named Senior Vice President, Chief Legal Officer, and Corporate Secretary in 2018. She was named as an executive officer in 2013. Ms. Barnes is responsible for all legal affairs of the company including SEC co pliance, corporate governance, IP strategy and management, licensing transactions, government contract negotiations and management and dispute resolution. She graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris, scholar of merit. Ms. Barnes received her B.S. in Natural Science with a concentration in biology and chemistry from UAB. Prior to joining the Company, Ms. Barnes worked for the UAB Research Foundation where she managed intellectual property, negotiated license transactions and facilitated the emergence of new companies based on university technology. Prior to employment at the UAB Research Foundation Ms. Barnes practiced corporate law with a prominent law firm in Birmingham, Alabama. Ms. Barnes is currently a Board member and the President of the Research Triangle Area Association of Corporate Counsel and regularly speaks at national conferences regarding the pharmaceutical business and at women’s success conferences. She is a 2010 graduate of MOMENTUM, an organization geared toward building leadership in women.
What is the salary of Alane Barnes?
As the Senior Vice President i Chief Legal Officer and Corporate Secretary of Biocryst Pharmaceuticals, the total compensation of Alane Barnes at Biocryst Pharmaceuticals is $1,331,090. There are 2 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
How old is Alane Barnes?
Alane Barnes is 54, she's been the Senior Vice President i Chief Legal Officer and Corporate Secretary of Biocryst Pharmaceuticals since 2018. There are 14 older and 8 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Alane Barnes's mailing address?
Alane's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Insiders trading at Biocryst Pharmaceuticals
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... oraz Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
What does Biocryst Pharmaceuticals do?
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
What does Biocryst Pharmaceuticals's logo look like?
Complete history of Ms. Barnes stock trades at Biocryst Pharmaceuticals
Biocryst Pharmaceuticals executives and stock owners
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jon Stonehouse,
President, Chief Executive Officer, Director -
Megan Sniecinski,
Senior Vice President, Chief Business Officer -
Alane Barnes,
Senior Vice President, Chief Legal Officer and Corporate Secretary -
Jon P. Stonehouse,
CEO, Pres & Exec. Director -
Yarlagadda Babu,
Senior Vice President - Drug Discovery -
William Sheridan,
Senior Vice President, Chief Medical Officer -
Dr. William P. Sheridan,
Chief Medical Officer & Sr. VP -
Dr. Yarlagadda S. Babu,
Chief Discovery Officer -
Stephen Aselage,
Independent Director -
Robert Ingram,
Independent Chairman of the Board -
Kenneth Lee,
Independent Director -
Nancy Hutson,
Independent Director -
George Abercrombie,
Independent Director -
Theresa Heggie,
Independent Director -
Helen Thackray,
Independent Director -
Dr. Helen M. Thackray FAAP, M.D.,
Chief R&D Officer -
Anthony Doyle,
Chief Financial Officer, Senior Vice President -
Alan Levin,
Independent Director -
Charles Gayer,
Senior Vice President, Chief Commercial Officer -
Allen Hodge,
Vice President and General Manager for the United States -
Michael Jones,
Executive Director - Finance, Principal Accounting Officer -
Alane P. Barnes,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Michael L. Jones,
Exec. Director of Fin. & Principal Accounting Officer -
Dr. Elliott T. Berger,
Sr. VP of Regulatory Affairs -
Robert C. Stoner,
VP of HR -
John D. Bluth,
Sr. VP of Investor Relations & Corp. Communications -
Anthony Doyle,
Sr. VP & CFO -
Sanj K Patel,
Director -
Stanley C Erck,
Director -
Fred E Cohen,
Director -
Lynne Powell,
Senior VP - CCO -
Thomas R Ii Staab,
Senior Vice President and CFO -
Bros. Advisors Lp Baker Bro...,
-
John L Higgins,
Director -
Felix Baker Bros. Investmen...,
-
Zola P Horovitz,
Director -
Robert S Lowrey,
Controller, PAO -
Steven K Galson,
Director -
Steve Aselage,
Director -
Brothers Life Sciences Capi...,
-
David Mc Cullough,
VP -
Bros. Capital (Gp), Llcbake...,
-
Stephen R Biggar,
Director -
Stuart Grant,
SR VP & CFO -
Beth C Seidenberg,
Director -
William W Featheringill,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Biotech Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Mike Mills,
Principal Accounting Officer -
Partners L P/Ilbiotechnolog...,
-
Carl L Gordon,
Director -
Charles E Bugg,
CEO -
J Claude Bennett,
President -
John A Montgomery,
Director -
Jonathan M Nugent,
VP Corp Communications -
W James Alexander,
SR. VP, Chief Medical Officer -
Randall B Riggs,
VP Business Development -
Michael A Darwin,
CFO -
Randolph C Steer,
Director -
Joseph H Jr Sherrill,
Director -
William M Iii Spencer,
Director -
Charles A Sanders,
Director -
Peder Jensen,
Director -
Amy E Mc Kee,
Director -
Machelle Sanders,
Director -
Vincent Milano,
Director